Irinotekan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a chemotherapy agent that targets the topoisomerase I pathway in colorectal malignancies. It is indicated for the following conditions:

• Colorectal cancer: used as part of combination regimens to reduce tumor burden and improve response rates.
• Metastatic colorectal cancer: administered to extend survival and control disease progression in advanced stages.

• Irinotecan is converted intracellularly to its active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex. This stabilisation prevents relegation of single‑strand DNA breaks, leading to accumulation of DNA damage, inhibition of DNA replication, and ultimately cell death in rapidly dividing cancer cells.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Diarrhea: may be severe and require supportive care.
• Nausea and vomiting: often managed with anti‑emetics.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Alopecia: hair loss during treatment cycles.
• Fatigue: generalized tiredness.
• Abdominal cramping.

Serious or Rare Side Effects

• Severe neutropenia with fever (febrile neutropenia).
• Life‑threatening colitis or severe diarrhea.
• Elevated liver enzymes indicating hepatic injury.
• Allergic reactions including anaphylaxis.
• Pulmonary toxicity such as interstitial pneumonitis.
• Hemorrhagic events due to thrombocytopenia.

Before initiating therapy, clinicians should assess baseline health status and monitor patients closely for known risks.

• Blood count monitoring: regular CBC to detect neutropenia.
• Liver function assessment: evaluate transaminases before and during treatment.
• Renal function evaluation: adjust dosing if renal impairment is present.
• Hypersensitivity avoidance: discontinue if severe allergic reaction occurs.
• Anti‑diarrheal prophylaxis: consider loperamide to mitigate severe diarrhea.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Irinotecan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin) may markedly reduce irinotecan exposure.
• Concurrent myelosuppressive agents increase risk of severe bone‑marrow suppression.
• Anticholinergic drugs can exacerbate irinotecan‑induced diarrhea.
• Live vaccines are contraindicated during treatment.
• High‑dose warfarin may potentiate bleeding risk.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole) may increase SN‑38 levels.
• UGT1A1 inhibitors can raise toxicity risk; dose adjustments may be needed.
• Other chemotherapy agents may require schedule coordination to avoid overlapping toxicities.
• Radiotherapy combined with irinotecan may heighten tissue damage.
• Use of growth‑factor support (e.g., G‑CSF) should be monitored for synergistic effects.